Degarelix and its therapeutic potential in the treatment of prostate cancer

References

• JemalASiegelRWardECancer statistics, 2008CA Cancer J Clin2008582719618287387
   PubMed Web of Science ®Google Scholar
• WiltTJMacDonaldRRutksIShamliyanTATaylorBCKaneRLSystematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancerAnn Intern Med2008148643544818252677
   PubMed Web of Science ®Google Scholar
• KlotzLActive surveillance for prostate cancer: trials and tribulationsWorld J Urol200826543744218813934
   PubMed Web of Science ®Google Scholar
• AntonarakisESBlackfordALGarrett-MayerEEisenbergerMASurvival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic reviewJ Clin Oncol200725314998500817971600
   PubMed Web of Science ®Google Scholar
• ThompsonIThrasherJBAusGAUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 updateJ Urol200717762106213117509297
   PubMed Web of Science ®Google Scholar
• LoblawDAVirgoKSNamRAmerican Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guidelineJ Clin Oncol200725121596160517404365
   PubMed Web of Science ®Google Scholar
• HugginsCStevensREJrHodgesCVStudies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate glandArch Surg194143209223
   Google Scholar
• MontironiRMagi-GalluzziCMuzzonigroGPreteEPolitoMFabrisGEffects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinomaJ Clin Pathol199447109069137525657
   PubMed Web of Science ®Google Scholar
• CastellónEClementiMHitschfeldCEffect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinomaCancer Invest200624326126816809153
   PubMed Web of Science ®Google Scholar
• SeidenfeldJSamsonDJHasselbladVSingle-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysisAnn Intern Med2000132756657710744594
   PubMed Web of Science ®Google Scholar
• McLeodDGHormonal therapy: historical perspective to future directionsUrology2003612 Suppl 13712667881
   PubMed Web of Science ®Google Scholar
• CookTSheridanWPDevelopment of GnRH antagonists for prostate cancer: new approaches to treatmentOncologist20005216216810794807
   PubMedGoogle Scholar
• HuirneJALambalkCBGonadotropin-releasing-hormone-receptor antagonistsLancet200135892951793180311734258
   PubMed Web of Science ®Google Scholar
• KlotzLBoccon-GibodLShoreNDThe efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancerBJU Int2008102111531153819035858
   PubMed Web of Science ®Google Scholar
• JiangGStalewskiJGalyeanRGnRH antagonists: a new generation of long acting analogues incorporating p-Ureido-phenylalanines at position 5 and 6J Med Chem200144345346711462984
   PubMed Web of Science ®Google Scholar
• BroquaPRivierePJMConnPMRivierJEAubertMLJunienJLPharmacological profile of a new, potent and long-acting gonadotropin-releasing hormone antagonist: degarelixJ Pharmacol Exp Ther200230119510211907162
   PubMed Web of Science ®Google Scholar
• SchwachGOudryNDelhommeSLuckMLindnerHGurnyRBiogradable microparticles for sustained release of a new GnRH antagonist – part I: screening commercial PLGA and formulation technologiesEur J Pharm Biophar2003563327336
   PubMed Web of Science ®Google Scholar
• WestonPMTHammondsJVaughton OlesenTKJensenJKEskerodOPerssonBEDegarelix; a novel GnRH antagonist tested in a multicentre, randomized dose-finding study in prostate cancer patientsBJU Int200494Suppl 25715217431
   PubMed Web of Science ®Google Scholar
• TammelaTIversenPJohanssonJPerssonBJensenOlsenTDegarelix Study groupDegarelix; a phase II multicenter, randomised dose-escalating study testing a novel GnRH receptor blocker in prostate cancer patientsEur Urol Suppl200543228
   Web of Science ®Google Scholar
• GittelmanMPommervillePJPerssonBEJensenJKOlesenTKDegarelix Study GroupA 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North AmericaJ Urol200818051986199218801505
   PubMed Web of Science ®Google Scholar
• Van PoppelHTombalBde la RosetteJJDegarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker–results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancerEur Urol200854480581318538469
   PubMed Web of Science ®Google Scholar
• DoehnCSommerauerMJochamDDrug evaluation: Degarelix – a potential new therapy for prostate cancerIDrugs20069856557216871466
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationDegarelix. Dec 29, 2008. Accessed on Feb 14, 2009. Available from: http://www.fda.gov/cder/Offices/OODP/whatsnew/Degarelix.htm
   Google Scholar
• BubleyGJIs the flare phenomenon clinically significant?Urology2001582 Suppl 15911502435
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationPlenaxis (abarelix for injectable suspension) Nov 25, 2003. Accessed on Feb 14, 2009. Available from: http://www.fda.gov/cder/drug/infopage/plenaxis/default.htm
   Google Scholar
• Speciality European Pharma2009Accessed on Feb 14, 2009. Available from: http://www.specialityeuropeanpharma.com
   Google Scholar
• Lu-YaoGLAlbertsenPCMooreDFSurvival following primary androgen deprivation therapy among men with localized prostate cancerJAMA2008300217318118612114
   PubMed Web of Science ®Google Scholar
• KeatingNLO’MalleyAJSmithMRDiabetes and cardiovascular disease during androgen deprivation therapy for prostate cancerJ Clin Oncol200624274448445616983113
   PubMed Web of Science ®Google Scholar
• PotoskyALKnopfKCleggLXQuality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes StudyJ Clin Oncol200119173750375711533098
   PubMed Web of Science ®Google Scholar
• SharifiNGulleyJLDahutWLAndrogen deprivation therapy for prostate cancerJAMA2005294223824416014598
   PubMed Web of Science ®Google Scholar
• MottetNPrayer-GalettiTHammererPKattanMWTunnUOptimizing outcomes and quality of life in the hormonal treatment of prostate cancerBJU Int2006981202716566812
   PubMed Web of Science ®Google Scholar
• SaigalCSGoreJLKrupskiTLHanleyJSchonlauMLitwinMSAnd the Urologic Diseases in America ProjectAndrogen deprivation therapy increases cardiovascular morbidity in men with prostate cancerCancer200711071493150017657815
   PubMed Web of Science ®Google Scholar